Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 12/20 | 0.76 |
| ▸ | BACE1 | P56817 | 12/20 | 0.76 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.74 |
| ▸ | ENPP1 | P22413 | 3/20 | 0.69 |
| ▸ | AURKA | O14965 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3873291 | 0.98 | ACHE (0.78) | ACHEBACE1PDE10AENPP1AURKA | |
| SCHEMBL11882354 | 0.92 | ACHE (0.88) | ACHEBACE1PDE10AENPP1AURKA | |
| SCHEMBL29357509 | 0.92 | ACHE (0.66) | ACHEBACE1PDE10AENPP1AURKA | |
| SCHEMBL4779400 | 0.89 | ACHE (0.61) | ACHEBACE1PDE10AENPP1AURKA | |
| SCHEMBL17030838 | 0.89 | ACHE (0.61) | ACHEBACE1PDE10AENPP1AURKA | |
| SCHEMBL4779574 | 0.87 | ACHE (0.63) | ACHEBACE1PDE10AENPP1AURKA | |
| SCHEMBL13790502 | 0.87 | ACHE (1.00) | ACHEBACE1PDE10AENPP1AURKA | |
| SCHEMBL5525750 | 0.87 | ACHE (0.74) | ACHEBACE1PDE10AENPP1AURKA | |
| SCHEMBL24510065 | 0.86 | ACHE (0.66) | ACHEBACE1PDE10AENPP1AURKA | |
| SCHEMBL2921150 | 0.86 | ENPP1 (0.77) | ACHEBACE1PDE10AENPP1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113924092-B | Quinoline and quinazoline compounds and methods of use thereof | 斯汀格瑞治疗股份有限公司 | 2025-03-18 | — | — | CN | disclosed |
| US-20070004763-A1 | AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-01-04 | — | — | US | disclosed |
| CN-1169795-C | Nitrogenous heterocyclic compounds | Э�ͷ���ҵ��ʽ���� | 2004-10-06 | — | — | CN | disclosed |
| CN-1208404-A | Nitrogenous heterocyclic compounds | KYOWA HAKKO KOGYO KK (JP) | 1999-02-17 | — | — | CN | disclosed |
| EP-0094766-B1 | QUINAZOLINE CARDIAC STIMULANTS | Pfizer Limited (GB) | 1986-12-30 | — | — | EP | disclosed |
| EP-0195667-A2 | Cardiotonic quinazoline derivatives | KYOWA HAKKO KOGYO KABUSHIKI KAISHA (JP) | 1986-09-24 | — | — | EP | disclosed |
| US-4542132-A | HYDROXY SUBSTITUTED | PFIZER INC. (US) | 1985-09-17 | — | — | US | disclosed |
| US-4489075-A | Cyclic sulfonamidoalkyl substituted 4-piperidinoquinazoline cardiac stimulants | PFIZER INC. (US) | 1984-12-18 | — | — | US | disclosed |
| EP-0094766-A2 | Quinazoline cardiac stimulants | Pfizer Limited (GB) | 1983-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004763-A1 | AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS | FLT3, BMX, ABL1 | ACHE 4535/4885BACE1 2700/4885PDE10A 2325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.